Status:
COMPLETED
A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM)
Lead Sponsor:
Takeda
Conditions:
Multiple Myeloma
Eligibility:
All Genders
Brief Summary
In this study, people with MM will be treated with ixazomib citrate according to their clinic's standard practice. The main aim of the study is to check for side effects from ixazomib citrate.
Detailed Description
This is a non-interventional, prospective, observational post-marketing surveillance study of ixazomib citrate in participants with MM. The study will assess the safety and effectiveness of ixazomib ...
Eligibility Criteria
Inclusion
- Participants with MM.
- Participants who are prescribed and initiate ixazomib citrate for the treatment of MM according to the ixazomib citrate South Korean product label.
Exclusion
- Participants treated with ixazomib citrate outside of the locally approved label in South Korea.
- Participants for which ixazomib citrate is contraindicated as per product label.
Key Trial Info
Start Date :
March 22 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 28 2023
Estimated Enrollment :
191 Patients enrolled
Trial Details
Trial ID
NCT04840680
Start Date
March 22 2021
End Date
August 28 2023
Last Update
July 24 2024
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Hallym University Sacred Heart Hospital
Anyang, South Korea, 14068
2
SOONCHUNHYANG UNIVERSITY HOSPITAL Bucheon
Bucheon-si, South Korea, 14584
3
Inje University Busan Paik Hospital
Busan, South Korea, 47392
4
Pusan National University Hospital
Busan, South Korea, 49241